Logo image of LJPC

LA JOLLA PHARMACEUTICAL CO (LJPC) Stock Fundamental Analysis

USA - NASDAQ:LJPC - US5034596040 - Common Stock

6.22 USD
0 (0%)
Last: 8/19/2022, 8:00:02 PM
Fundamental Rating

2

LJPC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. While LJPC seems to be doing ok healthwise, there are quite some concerns on its profitability. LJPC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LJPC had negative earnings in the past year.
LJPC Yearly Net Income VS EBIT VS OCF VS FCFLJPC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA 3.99%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LJPC Yearly ROA, ROE, ROICLJPC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 200 -200 -400

1.3 Margins

Industry RankSector Rank
OM -5.53%
PM (TTM) 8.54%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LJPC Yearly Profit, Operating, Gross MarginsLJPC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

LJPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
LJPC has less shares outstanding than it did 1 year ago.
LJPC has a worse debt/assets ratio than last year.
LJPC Yearly Shares OutstandingLJPC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
LJPC Yearly Total Debt VS Total AssetsLJPC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

LJPC has an Altman-Z score of -12.76. This is a bad value and indicates that LJPC is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for LJPC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.76
ROIC/WACCN/A
WACC9.48%
LJPC Yearly LT Debt VS Equity VS FCFLJPC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M -100M -150M

2.3 Liquidity

LJPC has a Current Ratio of 4.02. This indicates that LJPC is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.52 indicates that LJPC has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 3.52
LJPC Yearly Current Assets VS Current LiabilitesLJPC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for LJPC have decreased by 0.00% in the last year.
Looking at the last year, LJPC shows a very negative growth in Revenue. The Revenue has decreased by -33.79% in the last year.
Measured over the past years, LJPC shows a very strong growth in Revenue. The Revenue has been growing by 161.44% on average per year.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
Revenue 1Y (TTM)-33.79%
Revenue growth 3Y95.98%
Revenue growth 5Y161.44%
Sales Q2Q%-34.35%

3.2 Future

Based on estimates for the next years, LJPC will show a very strong growth in Earnings Per Share. The EPS will grow by 38.81% on average per year.
The Revenue is expected to grow by 6.65% on average over the next years.
EPS Next Y-92.84%
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%
EPS Next 5Y38.81%
Revenue Next Year-31.93%
Revenue Next 2Y-9.19%
Revenue Next 3Y-0.71%
Revenue Next 5Y6.65%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
LJPC Yearly Revenue VS EstimatesLJPC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
LJPC Yearly EPS VS EstimatesLJPC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LJPC. In the last year negative earnings were reported.
LJPC is valuated quite expensively with a Price/Forward Earnings ratio of 26.51.
LJPC is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.57, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 26.51
LJPC Price Earnings VS Forward Price EarningsLJPC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -120.41
LJPC Per share dataLJPC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

LJPC's earnings are expected to decrease with -5.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%

More info and screens

0

5. Dividend

5.1 Amount

LJPC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LA JOLLA PHARMACEUTICAL CO

NASDAQ:LJPC (8/19/2022, 8:00:02 PM)

6.22

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-15 2022-08-15/bmo
Earnings (Next)11-02 2022-11-02
Inst Owners0%
Inst Owner Change0%
Ins Owners6.25%
Ins Owner Change0%
Market Cap158.96M
Analysts43.33
Price Target6.35 (2.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 26.51
P/S 3.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -120.41
EPS(TTM)-0.03
EYN/A
EPS(NY)0.23
Fwd EY3.77%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.82
BVpS-2.72
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -5.53%
PM (TTM) 8.54%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 3.52
Altman-Z -12.76
F-Score7
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
EPS Next Y-92.84%
EPS Next 2Y-35.85%
EPS Next 3Y-5.61%
EPS Next 5Y38.81%
Revenue 1Y (TTM)-33.79%
Revenue growth 3Y95.98%
Revenue growth 5Y161.44%
Sales Q2Q%-34.35%
Revenue Next Year-31.93%
Revenue Next 2Y-9.19%
Revenue Next 3Y-0.71%
Revenue Next 5Y6.65%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A